Skip to main content
Category

Treatments

NIH Library of Medicine
ResearchTreatments

Nitroglycerin Plus Whole Intracranial Radiation Therapy for Brain Metastases in Patients With Non-Small Cell Lung Cancer: A Randomized, Open-Label, Phase 2 Clinical Trial

*March 2023* Results: Fifty patients were allocated to the control group, and 46 were allocated to the experimental group (NTG); among these, 26 (52%) had EGFRm in the control group and 21 (45.7%) had EGFRm in the NTG arm. In terms of the iORR, patients in the NTG group had a…
laurabbook@gmail.com
August 5, 2023
Onc Live
ResearchTreatments

Patritumab Deruxtecan Continues to Generate Responses in Previously Treated EGFR-Mutated NSCLC and HER3-Expression Breast Cancer

*March 2023* The antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) elicited responses in previously treated patients with EGFR-mutated metastatic or unresectable non–small cell lung cancer (NSCLC), according to updated data from a phase 1 trial (NCT03260491). Findings from a phase 1/2 trial (NCT02980341) also showed that the agent induced a response in…
laurabbook@gmail.com
August 5, 2023
Nature Communications
ResearchTreatments

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

*February 2023* Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance mutations. In the Phase III FLAURA study (NCT02296125), first-line osimertinib improved outcomes vs comparator EGFR-TKIs in EGFRm advanced non-small cell lung cancer. This analysis identifies acquired resistance mechanisms to…
laurabbook@gmail.com
August 5, 2023
OncLive
ResearchTreatments

Trastuzumab Deruxtecan Meets ORR End Point in HER2-expressing Advanced Solid Tumors

*March 2023* The antibody-drug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (Enhertu) met the prespecified target for objective response rate (ORR) and demonstrated durable responses in heavily pretreated patients with HER2-expressing advanced solid tumors in the phase 2 DESTINY-PanTumor02 trial (NCT04482309).1 The trial included previously treated patients with locally advanced, unresectable, or metastatic…
laurabbook@gmail.com
August 5, 2023
Science Direct
ResearchTreatments

Osimertinib in Non-Small Cell Lung Cancer (NSCLC) with Atypical EGFR Activating Mutations: A Retrospective Multicenter Study

*January 2023* Introduction Epidermal growth factor receptor (EGFR) mutations drive a subset of non-small cell lung cancer (NSCLC). Patients harboring the common EGFR mutations, deletion of exon 19 (Ex19del) and L858R, respond well to osimertinib, a third-generation tyrosine kinase inhibitor. However, the effect of osimertinib on NSCLC with atypical EGFR…
laurabbook@gmail.com
February 6, 2023